Success Stories: Engineering Breakthroughs in Brain Therapy: EB-2 NIW and EB1-B Secured for Indian Scientist

Client’s Testimonial:

“Thank you for all your help with the entire process!”

On July 17^th, 2024, and February 10^th, 2025, we received another EB-1B (Outstanding Professors and Researchers) and EB-2 NIW (National Interest Waiver) approvals for an Assistant Professor in the Field of Neural Engineering (Approval Notice).

General Field: Neural Engineering

Position at the Time of Case Filing: Assistant Professor

Country of Origin: India

State of Residence at the Time of Filing: Louisiana

Approval Notice Date: July 17^th, 2024 (EB1B); February 10^th, 2025 (NIW)

Processing Time: 2 days (EB1B) (Premium Processing Requested), 9 months, 16 days (NIW)

Case Summary:

We are pleased to share the successful outcome of both EB-2 NIW (National Interest Waiver) and EB1B (Outstanding Researcher/Professor) petitions secured for a distinguished researcher in neural engineering from India. The client’s work focuses on the development of brain-computer interface-based neuromodulation techniques aimed at advancing therapeutic interventions for complex brain disorders. At the time of filing, he was engaged in cutting-edge academic research and had already made significant strides in addressing challenges related to movement, cognitive, and mental health conditions through innovative, patient-centered approaches.

Research with Substantial Merit and National Importance & Well Positioned to Advance the Proposed Endeavor:

Upon reviewing the client’s background, NAILG recognized the national significance of his endeavor, which involves designing novel techniques to develop advanced BCI-based neuromodulation treatments. His work is aimed at improving patient outcomes in cases involving pathological cognitive, movement, and mental health disorders, conditions that are of growing concern in the United States.

The client’s contributions offer practical, forward-looking solutions to the nation’s ongoing brain health crisis. His research has received support from the National Institutes of Health (NIH), the Alzheimer’s and Related Diseases Research Award Fund (ARDRAF), and the U.S. Department of Veterans Affairs (VA) Biomedical Laboratory Research and Development (BLRD) program, which further demonstrates its importance at the national level.

NAILG also presented strong evidence of the client’s academic productivity and professional standing. He has authored 12 peer-reviewed journal articles (including 4 first-authored and 3 co-first-authored), one peer-reviewed conference paper, two preprints (1 first-authored and 1 co-first-authored), 8 abstracts (1 first-authored), and one patent application publication. His body of work has been cited 115 times to date, underscoring the impact and uptake of his contributions within the field.

To further support his qualifications, we highlighted his editorial and peer review activity. The client has completed at least 10 peer reviews and serves as a review editor for a reputable scientific journal, affirming his recognition as a trusted expert among academic peers.

Final Result:

With our assistance, the client obtained approvals for both his NIW and EB1B petitions. His testimonial describes him as holding “considerable significance in shaping the present and future of brain research and neural engineering, both within the United States and across the global scientific community.” NAILG is proud to have played a role in helping this outstanding researcher continue his impactful work in the U.S., and we look forward to seeing the difference his innovations will make in improving public health.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.